Intralytix, Inc.'s VRELysin™ bacteriophage therapy targeting vancomycin resistant Enterococci colonization in the gastrointestinal tract has entered a Phase 1/2a clinical trial at the University of Pittsburgh Medical Center in Pittsburgh, PA. The trial, registered under clinicaltrials.gov NCT05715619, is currently active, but not yet recruiting volunteers for Phase 2a.

For questions on the phage study, please contact infectiousdiseases@upmc.edu